ProShares Ultra NASDAQ Biotechnology
33 hedge funds and large institutions have $21.7M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
17% less capital invested
Capital invested by funds: $26.1M → $21.7M (-$4.39M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
57% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $24.6M
Holders
33
Holding in Top 10
1
Calls
$10.4M
Puts
$24.6M
Top Buyers
| 1 | +$1.98M | |
| 2 | +$560K | |
| 3 | +$466K | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$356K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
+$278K |
Top Sellers
| 1 | -$5.41M | |
| 2 | -$1.66M | |
| 3 | -$1.27M | |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$1.01M |
| 5 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$612K |